| Literature DB >> 31101087 |
Yuanyuan Li1,2, Qinyuan Li1,2, Guangli Zhang3, Huan Ma1,2, Yi Wu1,2, Qian Yi1,2, Lili Jiang1,2, Jiao Wan1,2, Fengtao Suo1,2, Zhengxiu Luo4.
Abstract
BACKGROUND: Staphylococcus aureus (S. aureus) is a common cause of bacteremia, which leads to significant morbidity and mortality. We investigated the relationship between time to positivity (TTP) and clinical outcomes in children with S.aureus bacteremia in the China.Entities:
Keywords: Children; S.aureus bacteremia; Time to positivity
Mesh:
Year: 2019 PMID: 31101087 PMCID: PMC6525363 DOI: 10.1186/s12879-019-3993-4
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Bar chart of TTP in Staphylococcus aureus bacteremia children. Out of a total of 84 SAB children, the number of children in each TTP period was plotted against the corresponding TTP, as shown. Details of the quantification have been described in Methods
Fig. 2Flow diagram of the population. As shown, a total of 84 cases were enrolled according to the inclusion and exclusion criteria, and then divided into early detection group (TTP ≤ 17 h) and late detection group (TTP > 17 h). The clinical characteristics of each group were then determined
Fig. 3Comparison of TTP in initial blood culture series according to in-hospital mortality and septic shock. (A) Kaplan-Meier tests were plotted against in-hospital mortality. Cumulative probability of time to positivity of in-hospital mortality patients are presented as the green curve, while survival patients are shown in blue. The difference is significant (P = 0.001). (B) Kaplan-Meier tests plotted against septic shock. The green curve represents the cumulative probability of time to positivity of patients with septic shock, and the blue curve represents patients without, the difference being significant (P = 0.001)
Fig. 4ROC curves of TTP to predict in-hospital mortality. The ROC curves were plotted according to the in-hospital mortality, and diagonal reference line is also shown. The X axis is 1-specificity, Y axis is sensitivity, and 16.955 h was the optimal cut-off point according to Youden’s index methodology. As shown above, ☆ points to the optimal cut-off, sensitivity is 61.5%, specificity is 91.5%, AUC (area under curve) is 0.776, with 95% CI 0.625–0.927
Clinical characteristics and outcomes comparison in early and late detection groups
| Variables | Early Detection Group ( | Late Detection Group | P |
|---|---|---|---|
| Demographic characteristics | |||
| Age, Median (IQR) | 75.00 (16.25–143.50) | 49.50 (8.49–124.75) | 0.275 |
| Weight, Median (IQR) | 23.00 (8.50–36.25) | 14.50 (7.50–32.75) | 0.506 |
| Male (n, %) | 11 (78.6%) | 44 (62.86%) | 0.262 |
| Underlying Conditions | |||
| Hematologic malignancy (n, %) | 2 (14.3%) | 8 (11.43%) | 0.765 |
| Congenital heart disease (n, %) | 4 (28.6%) | 10 (14.29%) | 0.193 |
| Neutropenia (n, %) | 2 (14.3%) | 8 (11.43%) | 0.765 |
| Primary immunodeficiency (n, %) | 2 (14.3%) | 5 (7.14%) | 0.394 |
| Chronic kidney disease (n, %) | 1 (7.1%) | 2 (2.86%) | 0.433 |
| Source of infection | |||
| Multiple sites | 5 (35.7%) | 19 (27.1%) | 0.519 |
| Pneumonia | 3 (21.4%) | 20 (28.6%) | 0.587 |
| Bone or joint | 0 (0.0%) | 13 (18.6%) | 0.081 |
| Skin or soft tissue | 0 (0.0%) | 9 (12.9%) | 0.158 |
| Primary bacteremia | 0 (0.0%) | 4 (5.7%) | 0.362 |
| Intravenous catheter | 2 (14.3%) | 2 (2.9%) | 0.068 |
| Catheter related infection | 1 (7.1%) | 1 (1.4%) | 0.203 |
| Incision | 0 (0.0%) | 2 (2.9%) | 0.525 |
| Endocarditis | 2 (14.3%) | 0 (0.0%) |
|
| CNS infection | 1 (7.1%) | 0 (0.0%) |
|
| APACHE II score ≥ 15 (n, %) | 5 (35.7%) | 22 (31.4%) | 0.755 |
| Prior antibiotic exposure (n, %) | 7 (50.0%) | 28 (40.0%) | 0.491 |
| Appropriate antibiotic exposure (n, %) | 1 (7.1%) | 12 (17.1%) | 0.348 |
| Immunosuppressants use (n, %) | 6 (42.9%) | 14 (20.0%) | 0.068 |
| Nosocomial infection (n, %) | 3 (21.4%) | 11 (15.7%) | 0.603 |
| Methicillin-resistance (n, %) | 4 (28.6%) | 25 (35.7%) | 0.610 |
| Hypoalbuminemia (n, %) | 1 ((7.1%) | 5 (7.1%) | 1.000 |
| Need for Treatments | |||
| Invasive Mechanical ventilation (n, %) | 6 (42.9%) | 12 (17.1%) |
|
| Vasoactive agent (n, %) | 7 (50.0%) | 13 (18.6%) |
|
| Outcomes | |||
| In-hospital mortality (n, %) | 8 (57.1%) | 5 (7.1%) |
|
| Septic shock (n, %) | 8 (57.1%) | 13 (18.6%) |
|
Length of hospitalization Median (IQR) | 17.00 (2.75–33.00) | 22.50 (14.75–37.00) | 0.151 |
ashowed difference in the early and late detection groups (P < 0.05)
b8 cases were bone or joint + skin or soft tissue, 5 cases were bone or joint + skin or soft tissue + pneumonia, 4 cases were skin or soft tissue + pneumonia, 5 cases were bone or joint + pneumonia, 2 cases were endocarditis + pneumonia
cincluding urethral catheters and thoracic drain tube
Logistic regression analyses of in-hospital mortality
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| OR | 95% C.I | P | OR | 95% C.I | P | |
| Early TTP | 17.333 | 4.293–69.984 | 0.000 | 97.494 | 4.477–2123.283 | 0.004 |
| Need for vasoactive agent | 34.444 | 6.475–183.236 | 0.000 | 40.513 | 2.988–549.355 | 0.005 |
| APACHE II score ≥ 15 | 6.625 | 1.817–24.151 | 0.004 | – | – | – |
| Neutropenia | 4.815 | 1.136–20.413 | 0.033 | – | – | – |
| Need for invasive mechanical ventilation | 8.540 | 2.263–32.233 | 0.002 | – | – | – |
| Immunosuppressants use | 12.273 | 3.208–46.955 | 0.000 | – | – | – |
| Hematologic malignancy | 4.815 | 1.136–20.413 | 0.033 | – | – | – |
Logistic regression analyses of septic shock incidence
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| OR | 95% C.I | P | OR | 95% C.I | P | |
| Early TTP | 5.846 | 1.730–19.761 | 0.004 | 6.757 | 1.094–41.730 | 0.040 |
| Need for vasoactive agent | 44.250 | 10.571–185.228 | 0.000 | 27.296 | 5.459–136.488 | 0.000 |
| APACHE II score ≥ 15 | 10.625 | 3.410–33.108 | 0.000 | 9.821 | 1.885–51.174 | 0.007 |
| Need for invasive mechanical ventilation | 11.611 | 3.435–39.253 | 0.000 | – | – | – |
| Neutropenia | 5.900 | 1.475–23.600 | 0.012 | – | – | – |
| Immunosuppressants use | 9.167 | 2.935–28.629 | 0.000 | – | – | – |
| Hematologic malignancy | 5.900 | 1.475–23.600 | 0.012 | – | – | – |